Liver-targeted chemo shows promise for tough bile duct cancer
NCT ID NCT03364530
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests giving chemotherapy drugs (gemcitabine and oxaliplatin) directly into the liver's main artery for people with advanced bile duct cancer that hasn't spread elsewhere. The goal is to shrink tumors while reducing side effects. About 40 adults who have already tried one standard treatment will receive this therapy. The main measure of success is whether tumors shrink at least 30% after 4 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine and oxaliplatin chemotherapy
What this could lead to
If successful, this could offer a new second-line treatment option to shrink liver tumors in patients with advanced bile duct cancer that hasn't spread.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. The treatment involves invasive catheter placement and carries risks like infection or liver damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLANGIOCARCINOMA NON-RESECTABLE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amiens University Hospital
RECRUITINGAmiens, France
Contact
-
Angers University Hospital
RECRUITINGAngers, France
Contact
-
Bordeaux University Hospital
RECRUITINGBordeaux, France
Contact
-
Centre Georges François Leclerc
RECRUITINGDijon, France
Contact
-
Hôpital Européen Georges Pompidou
RECRUITINGParis, France
Contact
-
Institut Gustave Roussy
RECRUITINGVillejuif, France
Contact
-
Uhmontpellier
RECRUITINGMontpellier, 34295, France
Contact Phone: •••-•••-•••• Email: •••••@•••••